The response to intravitreal brolucizumab on diabetic macular edema (DME) and macular ischemia was studied in treatment-refractory and treatment-naïve patients.
Methods
Patients with either recalcitrant (group 1) or treatment-naïve (group 2) DME were studied before and after intravitreal brolucizumab. All patients underwent a comprehensive ophthalmological examination including optical coherence tomography (OCT) and OCT-angiography (OCT-A). We compared the DME and macular/choriocapillaris ischemia before and after the loading dose.
Results
A total of 33 eyes of 26 patients were examined. 18 eyes were switched to brolucizumab, 15 eyes were treatment naive. All eyes responded with anatomical and functional improvement: group 1: 391 vs 298 μm (p = 0.005), 0.6 ± 0.4 logMAR vs. 0.4 ± 0.4 logMAR) (p = 0.01), group 2: 430 vs 281 μm (p = 0.0007), 0.5 ± 0.2 logMAR vs. 0.2 ± 0.2 logMAR (p = 0.004). In group 2 there was also significant improvement in retinal vascular parameters, especially in the central and inner circles of the ETDRS grid: central capillary density 6.55 vs 9.03 mm/mm2 (p = 0.008), inner 11.2 vs 13, 9 mm/mm2 (p = 0.02), central perfusion density 15.5% vs 20.7% (p = 0.02). Choriocapillaris flow deficit (CCFD%) also improved after the loading dose (40.3 vs. 35.3, p = 0.03). Although not statistically significant, there was also an improved foveal circularity.
Conclusion
Intravitreal brolucizumab leads to significant functional and anatomical improvement in diabetic macular edema and has also a beneficial effect on macular ischemia as shown by improvement in both retinal and choroidal perfusion.
SimDAKeanePAZarranz-VenturaJ, et al.Predictive factors for the progression of diabetic macular ischemia. Am J Ophthalmol2013; 156: 684–692.
2.
de CarloTEChinATBonini FilhoMA, et al.Detection of microvascular changes in eyes of patients with diabetes but not clinical diabetic retinopathy using optical coherence tomography angiography. Retina2015; 35: 2364–2370.
3.
FritscheLGIglWBaileyJN, et al.A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet2016; 48: 134–143.
4.
DiGWeihongYXiaoZ, et al.A morphological study of the foveal avascular zone in patients with diabetes mellitus using optical coherence tomography angiography. Graefes Arch Clin Exp Ophthalmol2016; 254: 873–879.
5.
FreibergFJPfauMWonsJ, et al.Optical coherence tomography angiography of the foveal avascular zone in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol2016; 254: 1051–1058.
6.
CennamoGRomanoMRNicolettiG, et al.Optical coherence tomography angiography versus fluorescein angiography in the diagnosis of ischaemic diabetic maculopathy. Acta Ophthalmol2017; 95: e36–e42.
7.
SamaraWAShahlaeeAAdamMK, et al.Quantification of diabetic macular ischemia using optical coherence tomography angiography and its relationship with visual acuity. Ophthalmology2017; 124: 235–244.
8.
BradleyPDSimDAKeanePA, et al.The evaluation of diabetic macular ischemia using optical coherence tomography angiography. Invest Ophthalmol Vis Sci2016; 57: 626–631.
9.
GarciaJMLimaTTLouzadaRN, et al.Diabetic macular ischemia diagnosis: comparison between optical coherence tomography angiography and fluorescein angiography. J Ophthalmol2016; 2016: 3989310.
10.
KodjikianLBellocqDBandelloF, et al.First-line treatment algorithm and guidelines in center-involving diabetic macular edema. Eur J Ophthalmol2019; 29: 573–584.
11.
BosciaFVerittiDIaculliC, et al.Management of treatment-naive diabetic macular edema patients: Review of real-world clinical data. Eur J Ophthalmol2024; 34: 1675–1694.
12.
MitchellPMcAllisterILarsenM, et al.Evaluating the impact of intravitreal aflibercept on diabetic retinopathy progression in the VIVID-DME and VISTA-DME studies. Ophthalmol Retina2018; 2: 988–996.
13.
BresslerSBOdiaIGlassmanAR, et al.Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: DRCR.net protocol I 5-year report. Retina2018; 38: 1896–1904.
14.
BonninSDupasBLaviaC, et al.Anti-vascular endothelial growth factor therapy can improve diabetic retinopathy score without change in retinal perfusion. Retina2019; 39: 426–434.
15.
ChatziralliITouhamiSCicinelliMV, et al.Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy. Eye (Lond)2022; 36: 692–703.
16.
IpMSDomalpallyASunJK, et al.Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology2015; 122: 367–374.
17.
FernandesCFCPereiraSDSLuizMB, et al.Camelid single-domain antibodies as an alternative to overcome challenges related to the prevention, detection, and control of neglected tropical diseases. Front Immunol2017; 8: 653.
18.
YokotaTMilenicDEWhitlowM, et al.Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res1992; 52: 3402–3408.
19.
RubsamAHosslLRauS, et al.Real-world experience with brolucizumab compared to aflibercept in treatment-naive and therapy-refractory patients with diabetic macular edema. J Clin Med2024; 13. DOI: https://doi.org/10.3390/jcm13061819
20.
CarosielliMCarnevaliAFallicoM, et al.Intravitreal brolucizumab for pachychoroid neovasculopathy associated with chronic central serous chorioretinopathy. Transl Vis Sci Technol2023; 12: 17.
21.
ChronopoulosAHuynhEAshurovA, et al.Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment. Eur J Ophthalmol2024; 34: 487–496.
22.
SorourOALevineESBaumalCR, et al.Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods. Surv Ophthalmol2023; 68: 147–174.
23.
ChenYZhuZChengW, et al.Choriocapillaris flow deficit as a biomarker for diabetic retinopathy and diabetic macular edema: 3-year longitudinal cohort. Am J Ophthalmol2023; 248: 76–86.
24.
AgarwalACorviFKumar MeniaN, et al.Choriocapillaris flow deficit in tubercular serpiginous-like choroiditis with and without paradoxical worsening. Ocul Immunol Inflamm2024; 32: 898–904.
25.
ChatziralliIDimitriouELambadiariV, et al.The impact of laboratory findings and optical coherence tomography biomarkers on response to intravitreal anti-VEGF treatment in patients with diabetic macular edema. Semin Ophthalmol2022; 37: 668–675.
26.
Schmidt-ErfurthUGarcia-ArumiJBandelloF, et al.Guidelines for the management of diabetic macular edema by the european society of retina specialists (EURETINA). Ophthalmologica2017; 237: 185–222.
27.
RoySTrudeauKRoyS, et al.New insights into hyperglycemia-induced molecular changes in microvascular cells. J Dent Res2010; 89: 116–127.
28.
JiaYBaileySTHwangTS, et al.Quantitative optical coherence tomography angiography of vascular abnormalities in the living human eye. Proc Natl Acad Sci U S A2015; 112: E2395–2402.
29.
BrahamIZKaouelHBoukariM, et al.Optical coherence tomography angiography analysis of microvascular abnormalities and vessel density in treatment-naive eyes with diabetic macular edema. BMC Ophthalmol2022; 22: 418.
30.
SunZYangDTangZ, et al.Optical coherence tomography angiography in diabetic retinopathy: an updated review. Eye (Lond)2021; 35: 149–161.
31.
HanRGongRLiuW, et al.Optical coherence tomography angiography metrics in different stages of diabetic macular edema. Eye Vis (Lond)2022; 9: 14.
32.
HsiehYTAlamMNLeD, et al.OCT angiography biomarkers for predicting visual outcomes after ranibizumab treatment for diabetic macular edema. Ophthalmol Retina2019; 3: 826–834.
33.
NanegrungsunkOPatikulsilaDSaddaSR. Ophthalmic imaging in diabetic retinopathy: A review. Clin Exp Ophthalmol2022; 50: 1082–1096.
34.
DurbinMKAnLShemonskiND, et al.Quantification of retinal microvascular density in optical coherence tomographic angiography images in diabetic retinopathy. JAMA Ophthalmol2017; 135: 370–376.
35.
ElnahryAGElnahryGA. Optical coherence tomography angiography of macular perfusion changes after anti-VEGF therapy for diabetic macular edema: a systematic review. J Diabetes Res2021; 2021: 6634637.
36.
WeinhausRSBurkeJMDeloriFC, et al.Comparison of fluorescein angiography with microvascular anatomy of macaque retinas. Exp Eye Res1995; 61: 1–16.
37.
Ghasemi FalavarjaniKIafeNAHubschmanJP, et al.Optical coherence tomography angiography analysis of the foveal avascular zone and macular vessel density after anti-VEGF therapy in eyes with diabetic macular edema and retinal vein occlusion. Invest Ophthalmol Vis Sci2017; 58: 30–34.
38.
ElhamakyTR. Comparison between intravitreal brolucizumab and aflibercept in the treatment-naive central involved diabetic macular edema: One-year real-life case series. Eur J Ophthalmol2024; 34: 797–802.
39.
MassengillMTCubillosSShethN, et al.Response of diabetic macular edema to anti-VEGF medications correlates with improvement in macular vessel architecture measured with OCT angiography. Ophthalmol Sci2024; 4: 100478.
40.
KarstSGDeakGGGerendasBS, et al.Association of changes in macular perfusion with ranibizumab treatment for diabetic macular edema: a subanalysis of the RESTORE (Extension) study. JAMA Ophthalmol2018; 136: 315–321.
41.
DastiridouAKarathanouKRigaP, et al.OCT angiography study of the macula in patients with diabetic macular edema treated with intravitreal aflibercept. Ocul Immunol Inflamm2021; 29: 926–931.
42.
SorourOASabrosaASYasin AlibhaiA, et al.Optical coherence tomography angiography analysis of macular vessel density before and after anti-VEGF therapy in eyes with diabetic retinopathy. Int Ophthalmol2019; 39: 2361–2371.
43.
SharmaAKumarNKuppermannBD, et al.Brolucizimab-leading an era of structural revolution for long-term VEGF suppression. Eye (Lond)2020; 34: 611–613.
44.
DugelPUKohAOguraY, et al.HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology2020; 127: 72–84.
45.
HolzFGDugelPUWeissgerberG, et al.Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study. Ophthalmology2016; 123: 1080–1089.
46.
WykoffCCMatsumotoHBarakatMR, et al.Retinal vasculitis or vascular occlusion after brolucizumab for neovascular age-related macular degeneration: A systematic review of real-world evidence. Retina2023; 43: 1051–1063.
47.
BodaghiBSouiedEHTadayoniR, et al.Detection and management of intraocular inflammation after brolucizumab treatment for neovascular age-related macular degeneration. Ophthalmol Retina2023; 7: 879–891.
48.
MonesJSrivastavaSKJaffeGJ, et al.Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology2021; 128: 1050–1059.
49.
AgarwalMMuralidharAShanmugamMP, et al.Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group. Indian J Ophthalmol2024; 72: 1156–1161.
50.
Vidal-OliverLGallego-PinazoRDolz-MarcoR. Astigmatism influences quantitative and qualitative analysis in optical coherence tomography angiography imaging. Transl Vis Sci Technol2024; 13: 10.
51.
NasimiSNasimiNGrauslundJ, et al.Real-world efficacy of intravitreal faricimab for diabetic macular edema: a systematic review. J Pers Med2024; 14. DOI: https://doi.org/10.3390/jpm14090913
52.
BrownDMBoyerDSDoDV, et al.Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet2024; 403: 1153–1163.
